Price (delayed)
$133.17
Market cap
$3.98B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.78
Enterprise value
$3.81B
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.Karuna understand there is a need for differentiated and
There are no recent dividends present for KRTX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.